BMO Capital Markets restated their buy rating on shares of Zimmer Biomet (NYSE:ZBH) in a report issued on Tuesday, January 30th. They currently have a $144.00 price objective on the medical equipment provider’s stock.
Other equities research analysts have also issued reports about the stock. Goldman Sachs Group raised shares of Zimmer Biomet from a sell rating to a neutral rating and set a $125.00 price objective on the stock in a report on Tuesday, December 19th. Stifel Nicolaus upgraded shares of Zimmer Biomet from a hold rating to a buy rating and boosted their target price for the company from $120.00 to $168.00 in a research report on Wednesday, January 31st. Canaccord Genuity restated a hold rating and set a $132.00 target price on shares of Zimmer Biomet in a research report on Friday, January 5th. Robert W. Baird restated a buy rating on shares of Zimmer Biomet in a research report on Wednesday, January 31st. Finally, TheStreet downgraded shares of Zimmer Biomet from a b- rating to a c+ rating in a research report on Friday, November 24th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of Buy and an average price target of $141.67.
Zimmer Biomet (ZBH) traded up $0.95 during midday trading on Tuesday, reaching $118.65. 337,815 shares of the company’s stock traded hands, compared to its average volume of 1,488,281. The company has a quick ratio of 0.83, a current ratio of 1.52 and a debt-to-equity ratio of 0.76. Zimmer Biomet has a fifty-two week low of $108.03 and a fifty-two week high of $133.49. The stock has a market capitalization of $23,472.71, a price-to-earnings ratio of 13.06, a P/E/G ratio of 2.04 and a beta of 1.08.
The firm also recently announced a quarterly dividend, which was paid on Monday, January 29th. Shareholders of record on Friday, December 29th were issued a dividend of $0.24 per share. The ex-dividend date of this dividend was Thursday, December 28th. This represents a $0.96 dividend on an annualized basis and a yield of 0.81%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 10.65%.
In other news, VP Chad F. Phipps sold 20,826 shares of the firm’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $115.95, for a total value of $2,414,774.70. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.07% of the stock is owned by corporate insiders.
Several institutional investors and hedge funds have recently made changes to their positions in ZBH. Bank of Nova Scotia Trust Co. purchased a new position in shares of Zimmer Biomet in the 3rd quarter valued at $112,000. FNY Managed Accounts LLC purchased a new position in shares of Zimmer Biomet in the 3rd quarter valued at $117,000. BB&T Investment Services Inc. purchased a new position in shares of Zimmer Biomet in the 2nd quarter valued at $144,000. Cerebellum GP LLC purchased a new position in shares of Zimmer Biomet in the 4th quarter valued at $133,000. Finally, Steward Partners Investment Advisory LLC purchased a new position in shares of Zimmer Biomet in the 3rd quarter valued at $140,000. Institutional investors and hedge funds own 86.36% of the company’s stock.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.